GLPwatch
Papers (9189)
Page 129 of 154, ranked by citation count.
- Estimating the True MACE Benefits From Tirzepatide in SURPASS-CVOT Using an Imputed Placebo Analysis of REWIND.
- Clinical Effectiveness of Oral Semaglutide in Women with Type 2 Diabetes: A Nationwide, Multicentre, Retrospective, Observational Study (Women_ENDO2S-RWD Substudy).
- The global clinical trial landscape for non-alcoholic fatty liver disease (NAFLD): current status and future prospects.
- Comparative study of dulaglutide single-use pen Ateos versus insulin degludec FlexTouch on learning and mock administration time in Japanese patients with type 2 diabetes mellitus - a <i>post-hoc</i> analysis.
- [Successful treatment of KCNJ11 neonatal diabetes without insulin].
- Semaglutide 2.4 mg in French people living with Class 3 obesity and comorbidities: Baseline characteristics and real-world safety data.
- Amylin receptors as therapeutic targets in obesity: Emerging peptide-based strategies.
- Predictive factors associated with three years of response to HbA1c goals with exenatide QW or insulin glargine: Post-hoc analysis of the DURATION-3 study.
- Cardiovascular Safety Profile of Semaglutide and Variations by Sex, Race, and Kidney Function: A Systematic Review and Meta-analysis.
- [Severe gastroparesia associated with the use of GLP-1 receptor agonists for weight loss].
- Endogenous GIP signaling is indispensable for DPP-4 inhibitor-mediated metabolic control in mice.
- <i>In vitro</i> cellular uptake and insulin secretion studies on INS-1E cells of exendin-4-loaded self-nanoemulsifying drug delivery systems.
- The effect of Semaglutide on mitochondrial function and insulin sensitivity in a myotube model of insulin resistance.
- Pre-stroke weight loss by glucagon-like peptide 1 receptor and neuropeptide Y receptor Y2 activation improves post-stroke functional recovery in male diabetic mouse models.
- A synergic GLP-1/Acylethanolamide-based combined therapy for MAFLD: Studies in rat models.
- Semaglutide and human reproduction: caution at the intersection of energy balance, ovarian function, and follicular development.
- Efficacy of Exenatide Administered Twice Daily in Body Mass Index Reduction in Patients with Type 2 Diabetes Mellitus.
- The Impact of Liraglutide, a GLP-1 Receptor Agonist, on High Glucose-Induced Inflammation, Apoptosis, Oxidative Stress, and NLRP3 Signaling.
- Liraglutide: can it make a difference in the treatment of type 2 diabetes?
- GLP-1 Receptor Agonists: Encouraging Signals for Treating Alcohol Use Disorder.
- Exenatide substantially improves proinsulin conversion and cell survival that augment Ins2<sup>+/Akita</sup> beta cell function.
- The Role of Race and Ethnicity in the Response to Metabolic Dysfunction-Associated Steatotic Liver Disease Treatment: A Review.
- [Effects of antidiabetic medications on metabolic-associated fatty liver disease].
- GLP1 receptor agonism alters growth and therapeutic response in prostate cancer.
- The Effectiveness of Semaglutide on a Composite Endpoint of Glycemic Control and Weight Reduction and Its Effect on Lipid Profile Among Obese Type 2 Diabetes Patients.
- Pharmacologic options for the treatment of overweight and obesity.
- Subclinical Changes in Type 2 Diabetes Patients with Heart Failure Stage A and B Treated with Oral Semaglutide.
- New Drug for Type 2 Diabetes.
- Research digest: pioneering an oral GLP-1 receptor agonist.
- Efficacy of newer agents in the glycaemic management of patients with type 2 diabetes.
- In type 2 diabetes, liraglutide reduced CV events at 5 y vs. glargine, glimepiride, or sitagliptin.
- Usefulness of circulating EPAC1 as biomarkers of therapeutic response to GLP-1 receptor agonists.
- Reactivity of N terminal histidine of peptides towards excipients/impurity of excipients: A case study of liraglutide excipient compatibility study.
- Are the cardiovascular properties of GLP-1 receptor agonists differentially modulated by sulfonylureas? Insights from post-hoc analysis of EXSCEL.
- Liraglutide Ameliorates Gamma Radiation-Induced Hepatic Damage in Rats: The Role of an Autophagy Flux Activation via LKB1/AMPK/mTOR Axis.
- Patient experiences with liraglutide for obesity and binge eating disorder-A qualitative study.
- Semaglutide and the pathogenesis of progressive neurodegenerative disease: the central role of mitochondria.
- Super response to liraglutide in people with obesity: A case report and literature review.
- Weight Loss, Obesity Medication, and Risk of Obesity-Associated Cancer: A Meta-Analysis of Randomized Controlled Trials.
- [Obesity treatment with liraglutide in a patient with Prader-Willi syndrome: a case report].
- Exploratory safety investigations in normal, freely moving Göttingen Minipigs using telemetry: Pharmacological validation.
- Glucagon-like peptide receptor-1 receptor agonists: The emerging fourth pillar in type 2 diabetes and chronic kidney disease?
- [Effects of glucagon-like peptide-1 receptor agonists on cardiovascular risk factors and the cardiovascular system].
- GLP-1 receptor agonists and cardiovascular risk in routine clinical practice.
- The metabolic effect of combined liraglutide treatment and lifestyle modification on obese adolescents in a tertiary center, Riyadh.
- Highlights From AHA 2023-New Risk Calculator, Semaglutide and CVD, and More.
- Once-Weekly Semaglutide with Lifestyle Intervention Results in Clinically Significant Weight Loss.
- A Blood Test for Alzheimer Disease, Repurposing GLP-1s, and Wildfire Smoke-Highlights From the AAIC.
- Repeated Withdrawal of a GLPR Agonist Induces Hyperleptinemia and Deteriorates Metabolic Health in Obese Aging UM-HET3 Mice.
- Effects of 6-month treatment with the GLP-1 receptor agonist liraglutide on 24-hour energy metabolism and body composition in adults with obesity.
- Liraglutide in the management of obesity: real world data (Portugal).
- Comparison of the effects of exenatide and insulin glargine on right and left ventricular myocardial deformation as shown by 2D-speckle-tracking echocardiograms.
- [Incretin analogues as a novel treatment strategy for Alzheimer's disease].
- Long term cost-effectiveness analysis of IDegLira in the treatment of type 2 diabetes patients compared to GLP-1RA added to basal insulin after IDegLira entered the national reimbursement drug list in China.
- Combined effect of continuous glucose monitoring and semaglutide: analysis of administrative claims.
- Regulation of nanoparticle exocytosis direction via receptors transfer: A novel strategy to enhance therapeutic efficacy of semaglutide.
- [Basal insulin degludec - liraglutide fixed ratio combination (Xultophy®)].
- Great Expectations: Semaglutide as Antidiabetic Weight Management in a Psychiatric Hospital.
- Semaglutide Initiation in a Type 2 Diabetes Mellitus, Post-Liver Transplant Patient.
- Intranasal Human Recombinant Modified Glucagon-Like Peptide-1: High Antihyperglycemic Activity and Duration of Action in Mice.